IRIDEX Corporation (IRIX) Earnings Call Transcript
November 17, 2026
Earnings Call Speaker Segments
Thank you, operator, and good afternoon to everyone. On today's call with me from Iridex are Patrick Mercer, our Chief Executive Officer, and Romeo Dizon, our Chief Financial Officer. Iridex issued its financial results for the third quarter, which ended October 3rd, 2026, after the market closed today. You can find that release in the Investor Relations section of the company's website. I'd like to point out that this discussion includes forward-looking statements as defined under the federal securities laws, and these are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statement that isn't strictly about historical facts counts as a forward-looking statement, and that covers things like our strategy, goals, and priorities, our financial outlook, product development and regulatory matters, sales trends, and the markets we serve. Such statements represent management's present expectations and assumptions, and they carry significant risks and uncertainties that might lead actual results or events to differ materially from what is expressed or implied today. Please don't place undue reliance on them. You can find a discussion of these risks in our most recent annual report on Form 10-K and our quarterly reports on Form 10-Q on file with the SEC. Other than as required by law, Iridex assumes no obligation to update or revise any forward-looking statements or financial projections, whether because of new information, future developments, or otherwise. We'll also refer during this call to certain non-GAAP measures, including adjusted EBITDA and adjusted operating expenses. Today's press release includes a reconciliation to the most directly comparable GAAP measure. This call contains time-sensitive information that is accurate only as of the date of this live broadcast, November 17th, 2026; with that, I'll hand the call over to Patrick.
Thanks, Trip. Good afternoon, everyone, and I appreciate you being with us today. The quarter we just wrapped up delivered several of the most meaningful structural strides our company has made in recent memory. Among the many recent developments, a key one involved completing the relocation of our manufacturing to the new headquarters in San Jose. Another notable item during the quarter was the substantial gain in gross margins, which rose 10 percentage points versus a year earlier and 8 percentage points on a sequential basis. In the third quarter of 2025, we booked a one-time write-off of roughly $0.8 million to cost of goods sold. Setting that item to the side, pro forma gross margin was 38.7%, which is a strong 370 basis point gain. All together, these cases show the real progress being made as we continue to rework and reposition the business, fulfilling our pledge to achieve sustainable profitability. Even as we keep making real headway on our longer-term strategic initiatives and operational improvements, the third quarter did carry some headwinds, with revenue coming in under expectations. The primary causes were the timing of international retina orders, international distributors drawing down probe inventory they had accumulated ahead of our manufacturing relocation, and continuing regulatory delays. Q3 came in below what we wanted, and that hurt all the more because it broke with the encouraging momentum from earlier in the quarter. No matter what drove it, we didn't hit the mark, and we're already moving aggressively to counter those pressures. The mission is simple: for the remainder of 2026, one goal will shape every major call we make — putting Iridex in position for stronger profitability in 2027. I'll spend some of today walking you through the steps we're taking and how the road ahead looks. As we examine our plans for what's next, operations are the right place to begin. We wrapped up the transfer of our manufacturing operations on October 5th, shifting them out of Mountain View into a newer facility in nearby San Jose that is more efficient and considerably cheaper. It was a complicated undertaking, and our team managed it without disrupting our quality systems. With the move now behind us, we've come through both the TÜV and BSI audits successfully, and we're currently waiting on the final audit reports and certificates, which will let us begin manufacturing for international markets at the new location. We expect this relocation to yield roughly $600,000 in annualized rent savings, and we see further manufacturing advantages materializing once the new site is fully folded into everyday operations. The new site provides a facility that fits the scale of the operations we plan to run. As we described during our previous call, shifting where we manufacture means we must re-register in several international markets, which produces brief periods in which shipments cannot go out under the new registration. To shield our distributors and their customers through those periods, we accumulated safety stock using the old address. That larger inventory is beginning to turn into revenue now that international regulatory clearances are being finalized, and we keep getting orders connected to blackout periods that are coming up. That ought to produce a cash flow tailwind as inventory working capital gradually converts back into cash. Our inventory investment, combined with third quarter revenue that came in below expectations, meant we used roughly $1 million of cash during the quarter. As safety stock turns into revenue and we gather the corresponding receivables, we are moving toward getting back to cash flow break-even. Developments in glaucoma remain very encouraging. Within the US, revenue for the G6 product family rose, helped by higher average selling prices and more system placements. Outside the US, probe orders declined during the quarter while distributors worked through inventory bought in the first half, a pattern we called out last quarter. In retina, US PASCAL sales stood out as the segment's highlight, with year-over-year sales up by approximately 50%. The remainder of the retina business faced challenges, since a combination of deferred orders, regulatory constraints, and competitive pricing in certain international markets weighed on sales. I will now go through each segment in more detail, beginning with glaucoma. We observed several bright spots in US glaucoma performance during the quarter, powered by the same three factors we noted last quarter: Medicare LCD tailwinds, targeted outreach through Medscout, and higher average selling prices. First, the Medicare LCD changes keep improving the reimbursement environment and are prompting physicians to consider MicroPulse TLT with G6 earlier in the treatment pathway. Our 2-year clinical follow-up data on MicroPulse TLT strengthens that shift. Data on outcomes over a longer horizon gives us a solid basis for educating physicians and supports bringing the therapy in earlier—including for certain patients whose disease is mild to moderate. Second, our utilization platform continues to hone where we focus commercially. Medscout lets our team zero in on accounts with mid-level utilization and on high-volume MIGS surgeons, since that is where we see the most obvious route to broader adoption; in addition, we left the American Academy of Ophthalmology conference with substantial physician interest and live commercial discussions, and we expect those to help drive adoption and utilization over the coming months. Third, pricing is still a significant factor. In 2025, the average selling price for the US G6 probe went up, and we've kept that elevated pricing steady all through 2026; in our view, this shows how much physicians value MicroPulse therapy. US G6 probe volume came to 6,900 units, about even with the same period a year earlier, and we placed 8 G6 systems in the US versus 7 in the prior-year quarter. Worldwide G6 probe volume totaled roughly 11,900 units, down from 14,900 a year earlier, and the drop was mainly due to how international distributors placed their orders. As for systems, we placed 28 G6 systems this quarter, compared with 30 in the third quarter of 2025. Turning to the specifics behind our international glaucoma results: across Europe, the Middle East, and Africa, order timing was the primary driver. Distributors pulled forward G6 console and probe purchases into the first and second quarters, which cut into third quarter demand, and the effect was compounded by stricter inventory and purchasing controls at one of our larger distribution partners. Supply constraints also caused some G6 probe illuminate orders to be fulfilled later than planned. In Germany and Austria, we continued to outperform plan, winning back business that our former distributor had handled. New G6 console placements remained competitive, particularly against the ART BOX platform. China's continuing economic challenges meant order activity stayed pretty level in Asia during Q3. Since Japanese customers had placed substantial orders in Q2 ahead of our headquarters move and the business transition tied to it, purchasing in Japan came in softer for the third quarter, which we had anticipated. Stocking orders from Korea and Malaysia submitted before the address change helped partially counterbalance softer demand elsewhere in the region. On an important note, all endoprobe backorders for China and Japan customers that had rolled over from the second quarter are now completely fulfilled; G6 probe sales in Latin America and Canada remained stable. Purchases from Peru and Chile offset softer buying in Brazil, where our distributor had stocked up during Q2. Following the commercial adjustments we implemented earlier this year, Canada continues to deliver steady results. On the whole, the drivers underpinning our glaucoma business remain sound: good reimbursement, expanding clinical evidence, sharper sales focus, and pricing discipline.
We remain focused on turning those strengths into steady growth in probe volume and additional system placements. Now turning to retina. Three priorities continue to guide our retina strategy: advancing the PASCAL upgrade cycle in the US, expanding PASCAL's international footprint, and securing regulatory approvals for next-generation platforms. In the US, we saw several encouraging developments this quarter. US PASCAL revenue grew about 50% compared with the prior year. Outside the US, retina ran into challenges concentrated in Asia and Europe. Let's start with Asia. In Japan, our partner shifted PASCAL shipments into Q4 after accumulating inventory ahead of our manufacturing relocation; that deferral covered a single order worth approximately $300,000, and we expect to ship it during the fourth quarter. In China, weak economic conditions, regulatory hurdles, and sluggish tender cycles are restraining activity; in India, registration delays keep our business there confined to PASCAL sales. In Europe, the Middle East, and Africa, medical retina confronted aggressive pricing pressure from larger competitors throughout Europe. PASCAL MDR certification delays also kept limiting sales in key markets, including Germany and Austria. We continue to expect PASCAL MDR approval in the first half of 2027 and anticipate solid demand once it is complete. In Latin America and Canada, PASCAL sales recovered following some early market disruption, and we expect further improvement as the rest of the year unfolds. We believe part of the retina impact from the third quarter—especially the shipments to Japan—will appear in the fourth quarter. Competitive pricing and regulatory timelines will likely take longer to resolve, and our plans account for that. I'd also like to touch on the Middle East: we removed that region from our guidance earlier this year, and recent developments in Saudi Arabia will continue to affect activity there. We'll continue serving customers in the region wherever we can, but our near-term outlook assumes no recovery. As we look at the rest of the year, particularly Q4, we expect our financial performance to benefit from several sources: the release of the remaining safety stock, open international orders, and the deferred Japan PASCAL shipments, plus the typical seasonal uptick we see at year-end. That said, we also expect these gains to be offset by the headwinds we discussed today continuing—specifically regulatory delays and competitor pricing pressure in retina, along with ongoing volatility in international ordering. So, we are revising our full-year 2026 revenue guidance to a range of $46 to $48 million, and that figure still excludes revenue from the Middle East. Even though that lowers what we expect for 2026, those very choices are why we believe 2027 will be a more profitable year for Iridex. Romeo will provide more detail shortly. Looking ahead to 2027, we expect to see the combined benefit of our cost-saving and margin initiatives for the first time, and that includes savings from the San Jose facility, the transfer of administrative functions, and the operating expense reductions we've made over the past 2 years. In addition to those efforts, we're reviewing and putting plans in place for further substantial cuts to operating expenses, and we expect those to bring our cost base down even more in 2027. Next, we anticipate a sizable improvement in gross margin as our main products move to third-party contract manufacturers; that transition remains on schedule to be completed in 2027, and once contract manufacturing covers our major products, we expect gross margins to rise. Third, we're conducting a thorough strategic review of both our product portfolio and our distribution model, with the goal of focusing more sharply on revenue streams that carry higher margins and greater profitability. As part of that work, we're looking at ways to streamline product lines and shrink the overall scale and complexity of what we offer. Simplifying what we offer will make operations more efficient and reduce the ongoing costs and headaches tied to obsolete products, managing inventory, and maintaining regulatory approvals in many markets. We're also reviewing how we distribute in select overseas markets so that our commercial structure aligns better with our profit targets. In some areas, this may mean accepting less revenue in exchange for better margins, lower cost to serve, and more predictable ordering. Ultimately, we expect these actions to deliver improved margins, a leaner cost base, and a business model that produces steadier cash flow, with the associated benefit in the range of $46 million to $48 million. I'll now turn the call over to Romeo for the financial review.
Thanks, Patrick, and good afternoon to everyone. Revenue on a total basis for Q3 2026 came in at $10.2 million, down from $12.5 million in Q3 2025. That third-quarter drop was driven mainly by international retina and fewer international probe orders, partly offset by growth in our US glaucoma business. Retina product revenue reached $5.1 million versus $6.7 million a year earlier. The decline stemmed from international markets, where deferred shipments in Japan, ongoing weakness in China, registration delays in India, and competitive pricing plus MDR regulatory timing in Europe all held back our revenues. Core product revenue for the Cyclo G6 product family was $3.2 million, compared with $3.5 million in Q3 2025. That decrease reflects lower international revenue as distributors worked through inventory bought earlier in the year, partly offset by higher US probe ASPs and higher system revenue. Other revenue totaled $1.9 million versus $2.2 million in the prior-year period, largely reflecting lower paid service revenue and no royalty revenue this period. Gross profit in Q3 was $4.3 million, a gross margin of 42.4% of revenue, versus $4.0 million, or 32.1%, in Q3 2025. As Patrick mentioned earlier, during Q3 2025 we booked a one-time, non-recurring, non-cash $0.8 million charge to cost of goods sold tied to an inventory write-down. Without that write-down, gross margin as a percent of revenue would have been 38.7%, roughly 370 basis points better than the prior year. That improvement reflects a more favorable geographic mix and sustained pricing discipline; we expect shifting to third-party contract manufacturers to become the next major driver of margin expansion as we progress through 2027. Operating expenses in Q3 were $5.5 million, basically flat against $5.4 million in the prior-year period. The quarter's net loss was $1.4 million, or $0.08 per share, versus a net loss of $1.6 million, or $0.09 per share, in the prior-year period. Non-GAAP adjusted EBITDA for Q3 was a loss of $0.6 million, compared with an adjusted EBITDA loss of $0.1 million in Q3 2025. On the balance sheet, we finished the quarter with cash and cash equivalents of $3.7 million as of October 3rd, 2026, versus $4.7 million at the close of the second quarter. Net cash used in operating activities was $1.0 million for the quarter. The primary driver was a $1.6 million inventory increase as we built safety stock to support distributors through registration blackout periods, along with lower revenue in the quarter. Going forward, cash utilization should fall significantly with stronger sales and a reversal of the inventory stocking process. On guidance: for the full year 2026, we now expect revenue in the range of $46 to $48 million. Just to remind everyone, our outlook leaves out revenue from the Middle East because of the conflict that is still going on in that region. We still anticipate that adjusted operating expenses — and those exclude depreciation, amortization, and stock-based compensation — will land somewhere between $19 million and $19.5 million for the full year; we aren't giving 2027 guidance today. Further ahead, we expect 2027 to show the full-year benefit from our reductions in operating expense, the relocation of our headquarters, and the gradual shift of our products to contract manufacturers, which should give us a more profitable Iridex; with that, I'll hand the call back to Patrick for closing remarks.
Thanks, Romeo. We’ve got a strong base going into next year. The move of our manufacturing is finished, and it’s producing the cost savings we expected, with additional benefits still to come once the site is fully integrated. Gross margin came up significantly versus the second quarter, and the safety stock we had built is now starting to generate revenue. Our glaucoma franchise keeps demonstrating its strength, with probe volume growth year to date, higher US pricing, and new 2-year MicroPulse TLT data that increases our confidence in the therapy’s long-term role. For the remainder of 2026, our priorities are clear: finish our international clearances, keep moving forward with our contract manufacturing transition, and get back to cash flow break-even. We expect to go into 2027 as a more efficient Iridex with improved margins, a lower cost base, and operating profits in a business model designed to generate cash. Thank you for your continued support of Iridex. We look forward to updating you on our progress next quarter. Operator, please open the line for questions.
Thanks, and good afternoon. There's plenty to cover. I'll aim for a higher-level, bigger-picture view. I do have a few questions. Let's begin with retina: over the last 3 quarters we've seen year-over-year declines in the double digits, and based on your guidance, Q4 looks like it will probably be near double-digit, if not a double-digit, decline. Granted, there are some moving parts affecting this year, but how are you thinking about organic growth for that segment? My sense was we were hoping for single digits or better if share gains were happening. How do you view that category, and I guess that likely carries into 2027 as well?
Hello Scott, thank you for asking. The current year, and particularly this quarter, has been difficult for us. Even as we move toward Q4, weakness in China is visible to us. To give an example, orders from China totaled $4 million last year. At present, we have roughly $400,000 from China this year. That has truly hurt us badly. We would have liked to have that $3.6 million. In Japan, we have witnessed considerable volatility stemming from our blackout periods and from coordinating with distributors to get those orders placed. Certain ones have been hesitant. Certain ones have preferred to hold off. As an example, Japan placed a stocking order in Q2, and then placed no orders at all during Q3. Energy prices are climbing because of the Iran war, and that's hit us in areas beyond the Middle East—Asia and Europe especially. We're managing those pressures, along with the regulatory holdups and some aggressive competitor pricing. You mentioned our view of '27—we're conducting a strategic review of our product lines, as we covered in the script, with the main goal of generating more profitable revenue streams. We won't sell in unprofitable regions anymore, we won't enter unprofitable countries, and we won't advance unprofitable product lines. That's the plan for 2027. We will examine ways to keep lowering our operating expenses, but our main emphasis will be on the profitable parts of the business, since that is what will really allow us to get past these challenges; our confidence in glaucoma remains. The growth in glaucoma is quite robust. Scott Henry (AGP): Let's stay on retina first. Okay. Let me finish this line of questioning if I can. Do you believe you're picking up share in the markets where you compete? The figures would indicate that you aren't, but I wanted to hear your view. In the US, we definitely are; we increased the IP, which is our flagship product, by 50%. Internationally, we've had difficulties stemming from the problems I mentioned earlier, while here in the US we're definitely facing them with our PASCAL system.
All right. I just want to get some clarity here, since I did notice the geographic segment breakout in the 10-Q, and I get what's happening in China and Japan. On Europe, when you mention regulatory delays, you're already selling in those markets. Are products being pulled from the market, which would hurt you, or is it that if new products are being held up, you'd still have your base business? It looks like you're actually losing business. Could you explain where the regulatory delays are hitting you?
Our new PASCAL product is our IP product, Iridex PASCAL, and it carries far more feature sets than the existing PASCAL. You're right that we sell the existing PASCAL in Europe today; however, many of those distributors know the new IP product is going to be approved, so they're holding off placing orders for those products. That's the difficulty. We've submitted everything to the notified bodies for MDR approval; our BSI audits are complete, our TÜV audit. Now we're simply waiting for those approvals, which we hope will arrive in Q1. Yes, you're right, we are selling in those markets. However, many distributors have told us they're waiting for approval before placing new orders for the new product.
Thanks, that helps. Now regarding the G6 business, you could see something of a bump in probes, especially during Q2 and maybe a bit in Q1. What's your thinking on probes for Q4? Do you figure we're back at a steady state, or are you expecting additional inventory burn in Q4?
For probe sales, and for G6 systems as well, Q4 is typically our biggest quarter, and I expect the volume of probe sales to go up in Q4.
Am I right in thinking you mean sequentially, or do you expect those to be up versus a year ago?
Yes, up against last year is what I expect, though sequential growth for sure.
Moving on to Q4.
Alright. On a year-over-year basis, that would suggest fairly solid growth. What about on systems? Would you expect a sequential rise as well as an increase versus last year? Q4 was especially strong for you last year. If I recall correctly, it was 44 systems.
That remains our view. It will definitely go up during this quarter, and we also expect a year-over-year increase. Everything we've talked about before regarding the LCD and treating more moderate patients earlier in the continuum of care. We received few G6 system orders from OUS in Q3, and we anticipate those figures will improve.
All right. From what I can tell, your guidance suggests revenue of $11.5 million to $13.5 million in Q4. Given current conditions, do you expect that to be adjusted EBITDA positive for operations?
Scott, Romeo here. Appreciate the question. For the quarter, yes — provided we hit the upper end of that revenue range, we will be, though not for the full year, given the losses taken in the prior three quarters.
Sure. Thanks, Romeo. So as a last question, if you begin steering sales in favor of profitable sales, which — unless you plan to grow your way to profitability — makes sense, that would suggest we'd see gross margins rise, or at minimum net margins, since the losses will either boost gross margin or be taken out of expenses. Where would you expect that to appear, because one of those metrics ought to get better — and roughly what size of improvement should we anticipate in 2027? Just in broad terms.
We anticipate that it will come from margin improvement and from lower operating expenses. Since we moved into these facilities back in October, with 6 months free rent and rents that are much lower, more than half of that is assigned to cost of sales. That will drive additional margin expansion. With the strategic product in our product portfolio, as Patrick mentioned earlier, we're going to cease selling low margins and concentrate on profit; that will contribute as well. We're also continually searching for ways to cut operating expenses, like maybe shifting more items overseas or similar. That's always a possibility.
All right, thanks to both of you for fielding all those questions. I appreciate it. Thank you.
Thank you, Scott.
Thank you, Scott.
At this point I'll hand the call back to the operator.
I’d like to thank everyone for being with us today, and we look forward to bringing you further updates on Iridex going forward. Thank you.
That brings us to the end of today's call, ladies and gentlemen. We appreciate everyone for joining in, and at this point you're free to disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete IRIDEX Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to IRIDEX Corporation earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.